Hybrid Nanocarriers for Neurological Disorders: Diagnostic & Therapeutic Approach

Recent Pat Nanotechnol. 2024;18(2):164-178. doi: 10.2174/1872210516666220825170125.

Abstract

Background: Around 1.5 billion people in the world are affected by complex neurological disorders, and the figure is increasing alarmingly due to unsatisfactory clinical outcomes. To date, no conventional formulation can show a promising effect on the control or prevention of neurodegeneration. However, Nano delivery tools have shown better penetration and profound action on the targeted area of the brain.

Methods: Although existing Nano therapeutic approaches are abundant but would not reach the clinic due to their improper bioavailability, BBB restricts its entry and causes improper biodistribution, so it is a challenge to use certain bioactive as a potential therapy in neurodegenerative disorders. Hybrid nanocarriers are nano-vesicular transported systems which could be utilized as carriers for the delivery of both hydrophilic and hydrophobic compounds. Available patents on nanodelivery for therapeutic approaches will also include in this review.

Results: Hybrid Nano delivery system may provide good stability to polar and nonpolar compounds and improve their stability.

Conclusion: This manuscript updates the available findings on the Nano vesicular system to deliver drugs for neurodegenerative disorders.

Keywords: Nanocarriers; bioactive; bioavailability; clinical outcomes.; hybrid; neurodegeneration.

Publication types

  • Review

MeSH terms

  • Drug Carriers / chemistry
  • Drug Delivery Systems
  • Humans
  • Nanoparticles* / therapeutic use
  • Neurodegenerative Diseases* / diagnosis
  • Neurodegenerative Diseases* / drug therapy
  • Patents as Topic
  • Tissue Distribution

Substances

  • Drug Carriers